Navigation Links
BioMS Medical Announces Third Quarter 2008 Results
Date:11/6/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Nov. 6 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the third quarter ended September 30, 2008. BioMS Medical, in partnership with Eli Lilly and Company (Lilly), is developing dirucotide (MBP8298), a drug for the treatment of MS undergoing pivotal trials in Canada, Europe and the U.S.

"The third quarter saw positive developments in the dirucotide development plan, with completion of the interim analysis resulting in a significant milestone payment from our partner Lilly," said Kevin Giese, President and CEO of BioMS Medical. "Dirucotide was also granted fast track designation by the U.S. FDA, another important achievement which could potentially accelerate the development and review process for this important MS drug."

Currently, BioMS is conducting three clinical trials and one open-label follow-on trial for dirucotide (MBP8298):

- MAESTRO-01: A randomized, double-blind pivotal phase II/III trial in

Canada and Europe evaluating dirucotide (MBP8298) for the treatment

of secondary progressive MS (SPMS). The study has completed full

recruitment of 611 patients at 47 trial sites in 9 countries. To

date, there have been nine positive safety reviews from the Data

Safety Monitoring Board (DSMB). Full analysis of this trial is

expected in the second half of 2009.

- MAESTRO-02: An open-label follow-on study to the MAESTRO-01 pivotal

trial. Eligible patients who have successfully completed the blinded,

placebo controlled MAESTRO-01 trial may choose to receive dirucotide

(MBP8298) on an un-blinded basis. To date, approximately 95% of

patients enrolled in MAESTRO-01 have proceeded to MAESTRO-02.

- MAESTRO-03: A U.S. pivotal phase III trial evaluatin
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... Florida (PRWEB) , ... June 30, 2015 , ... ... cannabis digital media company, launched “Cannavoices,” an unprecedented digital video and broadcast ... largest but also the most dynamic collection of legal medical cannabis stories ever ...
(Date:6/29/2015)... 30, 2015   Pharnext SAS today announced that ... the treatment of Charcot-Marie-Tooth Type 1A (CMT1A), is being presented ... Peripheral Nerve Society (PNS) Biennial Meeting at the Quebec Congress ... 27 - July 2, 2015. At Poster Viewing ... 1, 5p.m. to 7p.m. EDT: Poster 23: ...
(Date:6/29/2015)... ... June 29, 2015 , ... The global microfluidics market is ... period (2015 to 2020). The market is mainly driven by the rising geriatric ... R&D. However, lack of adequate healthcare and research infrastructure in emerging markets, dearth ...
(Date:6/29/2015)... WASHINGTON , June 29, 2015  AACC, ... to better health through laboratory medicine, is pleased ... journal, Clinical Chemistry , has increased to ... Reports. This increase places Clinical Chemistry ... and reflects the significant influence of the research ...
Breaking Biology Technology:Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3Pharnext's PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 3Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 4Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 5AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 2AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 3
... scientists at the National Institute of Standards and ... highly efficient piezoelectric material into a silicon microelectromechanical ... advances in sensing, imaging and energy harvesting. ... when fed electricity and, conversely, generates an electric ...
... Modern Mobility Aids, Inc. (OTCBB: MDRM) (the "Company") ... financing required to execute its closing agreement to acquire ... ("LumiGene"). Modern Mobility Aids, Inc. is a ... and development in the Bio-Pharma sector as well as ...
... The question of how many polyhedral nanocrystals of silver ... burning on many lips but the answer holds importance ... plasmonics! Researchers with the U.S. Department of Energy (DOE),s ... the door to a simpler approach for the fabrication ...
Cached Biology Technology:Tiny levers, big moves in piezoelectric sensors 2Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies 2Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies 3On the road to plasmonics with silver polyhedral nanocrystals 2On the road to plasmonics with silver polyhedral nanocrystals 3
(Date:6/30/2015)... -- Genisphere announced Tom Bliss ... develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss comes ... of the last 25 years in leadership positions at ... & Johnson. Tom started his career in Investment Banking, ... He graduated from Dartmouth College with a BA in ...
(Date:6/25/2015)... PRINCETON, N.J. , June 25, 2015  TAKE ... awarded a patent by the United States Patent and ... Data Standardization". This process leverages TAKE Solutions, Clinical Accelerators ... by over 50% (when compared to standardization without the ... At the heart ...
(Date:6/24/2015)... MARTIGNY, Switzerland , June 24, 2015 /PRNewswire/ ... strategic partnership with emerging biometric password solution one ... http://photos.prnewswire.com/prnh/20150623/225014LOGO one face in, ... offers a ground-breaking and affordable multifactor-authentication biometric answer ... speaker recognition technology, provided in partnership with KeyLemon, ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... world would help stave off an imminent global extinction ... Proceedings of the National Academy of Sciences ( www.pnas.org ... member organizations of the Alliance for Zero Extinction (AZE ... with imminent extinction, each of which is in need ...
... has its roots in yielding more food to feed more ... , His team's study appears in ... , The team made tomato plants over-express the gene, ... resulted in roots making better use of limited water, said ...
... and the National Human Genome Research Institute (NHGRI), ... (NIH), today launched a comprehensive effort to accelerate ... through the application of genome analysis technologies, especially ... Cancer Genome Atlas (TCGA), will begin with a ...
Cached Biology News:Pretreating rogue cancer cells with aspirin cripples their resistance to targeted therapy 2Anyway you slice it, tomatoes cut through drought with new gene 2NIH launches comprehensive effort to explore cancer genomics 2NIH launches comprehensive effort to explore cancer genomics 3NIH launches comprehensive effort to explore cancer genomics 4